Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review
- PMID: 28466678
- DOI: 10.1080/1028415X.2017.1321813
Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review
Abstract
Introduction: Alzheimer's disease (AD) is a neurodegeneration disorder characterized by progressive impairments of memory, language, reasoning, and other cognitive functions. Evidence suggests that omega-3 fatty acids may act as a possible protection factor in AD.
Objective: To evaluate the results available in the literature involving omega-3 fatty acids supplementation and its effect on cognitive function in AD patients.
Methods: A systematic review of MEDLINE (from PubMed), Excerpta Medica Database, and Cochrane Library databases was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Inclusion criteria consisted in original intervention studies, controlled by placebo, that assessed the impact of supplementation or dietary intake of omega-3 fatty acids on cognitive function, in humans with AD, without limitation for prime date of publication.
Results: Initial search resulted in 361 articles. Seven studies fully met the inclusion criteria. Most studies did not find statistically significant results for the omega-3 fatty acids supplementation compared to placebo, and those who show some benefit do it only in a few cognitive assessment scales. However, the effects of omega-3 fatty acids appear to be most effectively demonstrated in patients with very mild AD.
Conclusion: The effects of omega-3 fatty acids supplementation in mild AD corroborate epidemiological observational studies showing that omega-3 fatty acids may be beneficial in disease onset, when there is slight impairment of brain function. Although some studies have shown changes in scales of cognitive function in more severe cases, they are not enough to support omega-3 fatty acids supplementation in the treatment of AD.
Keywords: Alzheimer's disease; Cognition; Docosahexaenoic acid; Eicosapentaenoic acid; Neuroinflammation; Omega-3 fatty acids.
Similar articles
-
Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.Arch Neurol. 2006 Oct;63(10):1402-8. doi: 10.1001/archneur.63.10.1402. Arch Neurol. 2006. PMID: 17030655 Clinical Trial.
-
No Effect of Omega-3 Fatty Acid Supplementation on Cognition and Mood in Individuals with Cognitive Impairment and Probable Alzheimer's Disease: A Randomised Controlled Trial.Int J Mol Sci. 2015 Oct 16;16(10):24600-13. doi: 10.3390/ijms161024600. Int J Mol Sci. 2015. PMID: 26501267 Free PMC article. Clinical Trial.
-
Fish consumption and omega-3 fatty acid supplementation for prevention or treatment of cognitive decline, dementia or Alzheimer's disease in older adults - any news?Curr Opin Clin Nutr Metab Care. 2017 Mar;20(2):104-109. doi: 10.1097/MCO.0000000000000350. Curr Opin Clin Nutr Metab Care. 2017. PMID: 27977429 Review.
-
A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice.Neuroscience. 2007 Oct 26;149(2):286-302. doi: 10.1016/j.neuroscience.2007.08.018. Epub 2007 Aug 14. Neuroscience. 2007. PMID: 17904756
-
[Contribution of omega-3 fatty acids for memory and cognitive function].Nutr Hosp. 2014 Sep 1;30(3):467-77. doi: 10.3305/nh.2014.30.3.7632. Nutr Hosp. 2014. PMID: 25238820 Review. Spanish.
Cited by
-
The relationship between micronutrients and cognitive ability in an elderly population with mild cognitive impairment and Alzheimer's disease: a cross-sectional study.BMC Neurol. 2024 Oct 25;24(1):416. doi: 10.1186/s12883-024-03800-2. BMC Neurol. 2024. PMID: 39455919 Free PMC article.
-
Exploring the causal effects of serum lipids and lipidomes on lewy body dementia: a Mendelian randomization study.Front Endocrinol (Lausanne). 2024 Sep 19;15:1456005. doi: 10.3389/fendo.2024.1456005. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39363901 Free PMC article.
-
Fish consumption, cognitive impairment and dementia: an updated dose-response meta-analysis of observational studies.Aging Clin Exp Res. 2024 Aug 20;36(1):171. doi: 10.1007/s40520-024-02823-6. Aging Clin Exp Res. 2024. PMID: 39162889 Free PMC article.
-
Personalized Paths: Unlocking Alzheimer's via the Gut-Brain Axis.Visc Med. 2024 Aug;40(4):194-209. doi: 10.1159/000535869. Epub 2024 Apr 8. Visc Med. 2024. PMID: 39157730 Review.
-
Plasma lipidomics in early APP/PS1 female mouse model and its relationship with brain: Is it affected by the estrous cycle?Alzheimers Res Ther. 2024 Aug 14;16(1):183. doi: 10.1186/s13195-024-01549-x. Alzheimers Res Ther. 2024. PMID: 39143583 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous